uniQure (QURE) Set to Post Earnings on Wednesday

uniQure (NASDAQ:QURE) will likely be posting its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect uniQure to post earnings of ($0.9154) per share and revenue of $6.17 million for the quarter. Parties can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:30 AM ET.

uniQure Stock Performance

Shares of QURE stock traded up $0.31 during trading hours on Tuesday, hitting $23.28. The stock had a trading volume of 510,953 shares, compared to its average volume of 2,407,037. The firm has a market capitalization of $1.61 billion, a PE ratio of -5.81 and a beta of 1.06. uniQure has a twelve month low of $8.73 and a twelve month high of $51.72. The stock’s 50 day moving average is $34.05 and its 200 day moving average is $29.68. The company has a debt-to-equity ratio of 0.15, a current ratio of 10.01 and a quick ratio of 10.01.

Analyst Ratings Changes

Several analysts recently commented on QURE shares. Wall Street Zen downgraded shares of uniQure from a “hold” rating to a “sell” rating in a research report on Saturday, September 5th. The Goldman Sachs Group lowered their price objective on shares of uniQure from $46.00 to $31.00 and set a “neutral” rating on the stock in a research report on Wednesday, September 30th. UBS Group began coverage on shares of uniQure in a research note on Thursday, October 15th. They issued a “buy” rating and a $48.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating on shares of uniQure in a report on Tuesday, September 29th. Finally, William Blair raised shares of uniQure to a “strong-buy” rating in a report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $53.25.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA accepted uniQure’s biologics license application for ifezuntirgene inilparvovec and granted it Priority Review. The FDA set a PDUFA target action date of May 1, 2027, bringing the therapy closer to a potential U.S. approval. uniQure FDA announcement
• Positive Sentiment: If approved, the treatment could become the world’s first disease-modifying therapy for Huntington’s disease, a potentially significant commercial opportunity and milestone for uniQure’s gene-silencing platform. Fierce Biotech article
• Neutral Sentiment: uniQure plans to begin screening approximately 200 patients for a confirmatory trial by year-end. The planned study supports the regulatory pathway but also indicates that additional clinical execution and data-generation risks remain before commercialization. Blockonomi article
• Neutral Sentiment: Investors are also awaiting uniQure’s upcoming results update, scheduled for November 4, which could provide additional information on cash resources, development costs and the Huntington’s program. uniQure results update article
• Negative Sentiment: The FDA filing acceptance is not an approval. The long wait until the May 2027 decision, the need for confirmatory data and the therapy’s prior clinical and regulatory uncertainties may explain why some traders sold the stock despite the Priority Review designation. MSN article

About uniQure

uniQure N.V. is a biotechnology company focused on developing gene therapies for serious and life-threatening diseases. The company uses adeno-associated virus (AAV) vectors and other genetic medicine technologies to deliver therapeutic genes intended to address the underlying causes of disease.

uniQure’s best-known product is HEMGENIX, a gene therapy for adults with hemophilia B caused by factor IX deficiency. HEMGENIX was developed by uniQure and is commercialized by CSL Behring under a global licensing agreement.